🌙
Type 2 Diabetes in Ramadan — Risk Stratification & Medication Adjustment Pre-Ramadan assessment · IDF-DAR / BIMA risk categories · drug-by-drug dose timing · when to break the fast · Diabetes & Primary Care 2023
Progress 0 / 9
The full reasoning pathway — assess risk 6–8 weeks before Ramadan, decide if it is safe to fast, then adjust each medication to iftar/suhoor — and agree when to break the fast. Educate, and safety-net.StartDecisionInvestigateActionReferStop / Admit
PresentationPerson with T2DM intends to fast
~116 million people with diabetes fast worldwide. Most will fast despite risk. Offer a structured pre-Ramadan assessment 6–8 weeks before; document the discussion and advice given.
Step 1 · Decision · Risk stratify (IDF-DAR / BIMA)Very high · high · moderate/low risk?
Stratify on diabetes type, hypo risk, medications, complications, comorbidities, social/work circumstances and prior fasting experience.
Category 1 — very high
MUST NOT fastStrongly advise against
Poorly-controlled T1D, recent DKA/HHS/severe hypo (3m), hypo unawareness, advanced macrovascular disease, CKD 4–5, T2D needing insulin without safe fasting experience, pregnancy. If insists → specialist, structured education, SMBG, break fast if hypo/hyper.
Category 2 — high
SHOULD NOT fastIndividualise carefully
Sustained poor control, T2D on insulin with safe-fasting experience, T2D on SGLT2i (consider pausing), CKD 3, stable macrovascular disease. Education, SMBG, dose adjustment if proceeds.
Category 3 — moderate/low
Decision = patientLikely able to fast
Well-controlled T2D on diet, metformin, DPP-4i, GLP-1 RA, pioglitazone, acarbose; SU or basal insulin (moderate — regular SMBG). Adjust meds & advise.
Step 7 · if fasting — adjust meds
Step 7 · Action · medicationMove the bigger dose to iftar; favour low-hypo agents
Metformin: same total — OD at iftar; BD iftar+suhoor; TDS combine afternoon+evening at iftar (MR at iftar). SU: switch to gliclazide/glimepiride (avoid glibenclamide); OD at iftar, reduce if well-controlled; BD reduce suhoor dose. SGLT2i: take at iftar, extra fluids, caution if dehydration risk. DPP-4i / GLP-1 RA / pioglitazone: no change. Glinides: redistribute to iftar+suhoor.
Break the fast if…BG <3.9 or >16.7 mmol/L · hypo symptoms · acute illness
Advise breaking the fast immediately if blood glucose <3.9 or >16.7 mmol/L, any symptoms of hypoglycaemia, or an acute illness develops. Checking blood glucose does not break the fast. Resume when health back to normal.
Step 8 · education & modifiable factors
Step 8 · Education & modifiable factorsSafe fasting habits
Structured pre-Ramadan education + SMBG training (and a meter). Eat a balanced suhoor as late as possible with complex carbs; avoid large sugary iftar meals; maintain hydration between sunset and dawn; moderate activity (heavy exertion late in the fast risks hypos — consider timing around taraweeh prayers). Don't stop essential non-diabetes meds without advice; recognise religious exemption.
Step 9 · review & safety-net
Step 9 · Review & safety-netMonitor & when to break/seek help
Break the fast and check glucose for hypo symptoms or BG <3.9 (treat) or >16.7 mmol/L; 999 for features of DKA/HHS (vomiting, drowsiness, very high glucose/ketones). Encourage regular SMBG (it does not invalidate the fast). Review control after Ramadan and revert medication timing/doses. Start any new agent 6–8 weeks before, not during, Ramadan.
⚠️ Fasting is a shared decision. Those whose health is harmed by fasting are religiously exempt and may pay fidyah or do non-consecutive/winter fasts. Initiate any new antidiabetic agent 6–8 weeks before Ramadan, not during it.
1
Safety

When to Break the Fast & the Risks of Fasting

Before anything else, every fasting patient must know the non-negotiable rules for breaking the fast and the risks they're balancing.

Break the fast immediately if BG < 3.9 mmol/L — impending hypoglycaemia. Treat and do not continue the fast.
Break the fast if BG > 16.7 mmol/L — significant hyperglycaemia.
Break the fast for any hypo symptoms — sweating, tremor, palpitations, confusion — even if a meter isn't to hand.
Break the fast if an acute illness develops — see the Sick Day Rules pathway; resume when health is back to normal.
DKA / euglycaemic DKA & HHS Risk rises with dehydration and SGLT2i use — DKA can occur with near-normal glucose. Urgent admission if suspected.
Dehydration & thrombosis Long summer fasts (10–21h in the UK) risk dehydration, AKI and thrombosis — emphasise hydration between iftar and suhoor.
ℹ️ Checking blood glucose does NOT invalidate the fast — reassure patients so they monitor freely. The key fasting risks are hypoglycaemia, hyperglycaemia, dehydration/thrombosis, DKA (incl. euglycaemic) and HHS.
The <3.9 / >16.7 mmol/L break-fast thresholds and the "acute illness → break fast" rule come directly from the IDF-DAR practical guidelines and are the core safety messages of any Ramadan consultation. Reassuring patients that finger-prick testing doesn't break the fast removes the commonest barrier to safe self-monitoring during Ramadan.
2
Diagnose

Pre-Ramadan Assessment & Risk Stratification

Offer a structured pre-Ramadan education session 1–2 months (6–8 weeks) before. It reduces hypoglycaemia, supports weight loss and improves control. Stratify risk first.

Factors to weigh
Type of diabetes · individual hypo risk · current medications · complications/comorbidities · social & work circumstances · previous fasting experience.
Category 1 — very high
Poorly-controlled T1D; DKA/HHS or severe/disabling hypo in last 3m; hypo unawareness; advanced macrovascular disease; CKD 4–5; insulin-treated T2D without safe-fasting experience; pregnancy in pre-existing DM or insulin/SU-treated GDM; acute illness; frail elderly. MUST NOT fast
Category 2 — high
Well-controlled T1D; T2D with sustained poor control (HbA1c >75 for >12m); insulin-treated T2D with safe-fasting experience; T2D on SGLT2i; stable macrovascular disease; CKD 3; metformin/diet-controlled GDM. SHOULD NOT fast
Category 3 — moderate/low
Well-controlled T2D on diet/lifestyle, metformin, DPP-4i, GLP-1 RA, pioglitazone, acarbose; 2nd-gen SU or basal insulin (moderate — regular SMBG). May fast — patient's discretion
Religious framing
In every category, patients should follow medical opinion where the advice is not to fast due to high probability of harm. A risk calculator is in IDF-DAR chapter 5 if uncertain.
The IDF-DAR / British Islamic Medical Association three-tier risk stratification is the backbone of safe Ramadan diabetes care: it tells you who must not fast, who should not, and who may with adjustment. Doing the assessment 6–8 weeks ahead leaves time to switch high-hypo-risk drugs, trial fasting, and arrange education — none of which can be done safely once Ramadan has started.
3
Diagnose

Monitoring & Who Is Exempt From Fasting

Exempt groups
Those for whom fasting is detrimental are religiously exempt: frail/elderly, children, pregnant & breastfeeding women, and people with significant comorbidities.
SMBG — when to check
Check several times a day: pre-dawn (suhoor), morning, midday, mid-afternoon, pre-sunset (iftar), 2 hours after iftar, and any time symptomatic or unwell. Testing does not break the fast.
Trial fast
Patients can do a 1–2-day trial fast in the month before Ramadan and review the effect on glucose.
Non-consecutive / winter fasts
Those whose conditions are exacerbated can do non-consecutive fasts, or switch to the winter months when fasts are shorter.
Fidyah
Those unable to fast may pay fidyah (a charitable donation, ~£5 per missed fast) and can participate in other acts of charity.
Document
If the patient chooses to fast despite risk, record this and the advice given in the notes.
Knowing the exemptions and alternatives (non-consecutive fasts, winter fasting, fidyah) lets you offer genuinely patient-centred advice rather than a blunt "don't fast". Most people with diabetes will fast regardless, so the realistic goal is risk-minimisation plus clear documentation that informed advice was given.
4
Treat

Medication 1 — Metformin & Sulfonylureas

General principle: the bigger dose moves to iftar, and favour agents with a low hypoglycaemia risk. The two key adjustments:

Metformin — total dose UNCHANGED
Re-time around iftar/suhoor
OD → take at iftar. BD → iftar + suhoor. TDS → morning dose at suhoor, combine afternoon + evening at iftar. MR/prolonged-release → take at iftar.
Sulfonylurea — hypo risk
Switch & reduce caution
Switch to a newer SU (gliclazide, glimepiride) where possible; avoid glibenclamide. OD → take at iftar, reduce dose if well-controlled. BD → iftar dose unchanged, reduce the suhoor dose.
SU combination tablets
Reduce / omit morning
Once-daily SU combination → take at iftar, consider reducing dose by 50%. Twice-daily SU combination → omit the morning dose, take the normal dose at iftar.
ℹ️ Metformin's glucose-lowering doesn't depend on meal timing and it carries minimal hypo risk, so only the timing changes. Sulfonylureas are the main oral hypo culprit during fasting — hence switching agent and trimming the pre-dawn (suhoor) dose.
The suhoor dose is the dangerous one: a sulfonylurea taken pre-dawn acts through the long daytime fast with nothing to eat, so it's reduced or omitted, while the iftar dose (taken with the evening meal) is safer and largely preserved. Glibenclamide is specifically avoided because its long action and high hypoglycaemia rate make it the worst SU for fasting.
5
Treat

Medication 2 — SGLT2i, Incretins, Glinides & Pioglitazone

SGLT2 inhibitors
No dose change — take with iftar. Drink extra clear fluids in non-fasting hours. Use with caution if at risk of fluid depletion; many stratify SGLT2i patients as high risk and consider pausing during Ramadan (euglycaemic DKA risk).
DPP-4 inhibitors
No dose modifications (low hypo risk) — e.g. sitagliptin, linagliptin, alogliptin.
GLP-1 receptor agonists
No dose modifications. If on oral semaglutide (Rybelsus), take the tablet at iftar and wait 30 minutes before eating.
Pioglitazone (TZD)
No dose modifications — can be taken with iftar or suhoor.
Prandial glucose regulators (glinides)
e.g. repaglinide. Three-times-daily dosing may be reduced/redistributed to two doses taken with iftar and suhoor.
Acarbose
Low hypo risk; take with meals (iftar/suhoor). Generally no specific change.
The incretin-based agents (DPP-4i, GLP-1 RA), pioglitazone and acarbose are favoured in Ramadan precisely because they don't cause hypoglycaemia, so they generally need no dose change. SGLT2 inhibitors are the exception — their diuretic effect risks dehydration and euglycaemic DKA over a long fast, which is why many clinicians up-stratify these patients and consider pausing the drug.
6
Treat

Medication 3 — Insulin-Treated T2DM

Insulin-treated T2D is at least high risk (Category 1–2). Proceed only with experience of safe fasting, education and SMBG — ideally with specialist input.

Basal insulin
Moderate risk with regular SMBG. Give at iftar; reduce the dose by ~15–20% if well-controlled to protect against daytime hypo.
Basal–bolus
Keep basal (reduced as above); give bolus with iftar and (smaller) with suhoor; omit the daytime (lunch) bolus as no meal is eaten.
Premixed / biphasic insulin
Give the usual evening dose at iftar; at suhoor give a reduced dose (often ~50% of the former morning dose). Reverse the larger/smaller timing so the bigger dose is at iftar.
Hypo monitoring
Intensify SMBG (incl. mid-afternoon, the highest-risk time). Break the fast if BG <3.9 mmol/L.
Who needs specialist input
No prior safe-fasting experience, brittle control, recurrent hypo, or T1D → refer to the diabetes team before Ramadan.
ℹ️ Detailed insulin titration in fasting is specialist territory — this is a primary-care framework. Use the diabetes team for any insulin-treated patient without a track record of safe fasting.
Insulin is the highest-hypo-risk therapy during fasting, so the universal moves are to reduce basal modestly, omit the daytime prandial dose (there's no daytime meal), and shift the larger premix dose to iftar. Because individual regimens vary so much, insulin-treated patients without proven safe fasting belong with the specialist team.
7
Lifestyle

Diet, Hydration & Exercise During Ramadan

Eat suhoor as late as possible A late pre-dawn meal shortens the effective daytime fast and reduces hypo/hyperglycaemia swings.
Choose slow-release carbs High-fibre, starchy foods that release energy slowly — chapatis, rice, oat cereals, grains, seeds, beans & pulses.
Stay well hydrated Drink plenty of water between iftar and suhoor; minimise caffeine (diuretic) to avoid dehydration.
Avoid fried & sugary foods Limit fried items (pakoras, samosas) and sugary foods; use Ramadan as a chance to make healthier choices.
Go easy on dates Don't over-consume dates at iftar — they're high in sugar and spike glucose.
Plenty of fruit & vegetables Include fresh fruit, vegetables and salads for fibre and satiety.
Light-to-moderate exercise Advisable; avoid strenuous activity during fasting hours and the period just before iftar (hypo risk).
Tarawih prayers count The physical activity of nightly prayers adds up — factor it into hypo risk after iftar.
A Ramadan nutrition plan — late suhoor, slow-release carbohydrate, good hydration and moderate sugar — flattens the glucose excursions that make fasting risky, while still respecting the cultural foods of the month. Counselling on dates and fried foods is practical and specific, which is what makes the advice land.
8
Refer

Referral, New Medication Timing & Specialist Input

Diabetes specialist team
Type 1 diabetes, insulin-treated T2D without safe-fasting experience, recurrent/disabling hypoglycaemia, advanced complications, or CKD 4–5 who still wish to fast.
Initiate new agents early
Any new antidiabetic medication should ideally be started 6–8 weeks before Ramadan, not during it, so tolerance & effect are known.
Consider switching agents
Pre-Ramadan, consider moving high-hypo drugs (glibenclamide, certain insulins) to lower-risk alternatives (DPP-4i, GLP-1 RA, gliclazide).
Pregnancy
Pregnant women are exempt; pre-existing diabetes or insulin/SU-treated GDM in pregnancy is very high risk → specialist obstetric/diabetes care.
Community / cultural working
Work with local religious scholars and community leaders; deliver group education and Ramadan-specific leaflets where there's a large fasting population.
Acute illness in Ramadan
New illness while fasting → break the fast, apply Sick Day Rules, and resume fasting once recovered.
Starting new agents 6–8 weeks ahead is a recurring theme because you never want to discover a drug's hypoglycaemia or GI effects mid-fast. Engaging community and faith leaders is evidence-based: it improves reach and trust, and embeds the safety messages where patients actually hear them.
9
Safety

Fasting & Illness — Shared Decision & Safety-Netting

An individual's decision to fast should weigh spiritual benefit against the risk of exacerbating illness. Frame it as a shared decision and safety-net clearly.

Break / abstain if…
The illness is worsened by fasting, recovery is delayed by fasting, or there's substantial fear of either — judged by prior experience, common knowledge, or a clinician's advice.
Break the fast now
BG <3.9 or >16.7 mmol/L, hypo symptoms, or acute illness (restate from Step 1).
Resume when well
Resume fasting when health is back to normal; if unsure, seek medical advice.
COVID / vaccines
Receiving a COVID-19 (or other) vaccine does not invalidate the fast.
Reassure the exempt
Those who can't fast can give donations, feed others, and pay fidyah — they're not failing their faith.
Document & follow up
Record the risk category, the plan, the advice given, and arrange review during/after Ramadan.
The "break/abstain if fasting worsens illness or delays recovery" framework is the religiously-grounded counterpart to the medical risk stratification, and quoting it (with the reassurance that testing and vaccines don't break the fast) is what makes the consultation both safe and culturally respectful. Documenting the shared decision protects the patient and the clinician.
Educational use only. Pathway based on: Gilani A (2023) How to manage diabetes in Ramadan (updated March 2023). Diabetes & Primary Care 25: 27–9 · IDF-DAR (2021) Diabetes and Ramadan: Practical Guidelines · British Islamic Medical Association (2020) Ramadan Rapid Review risk table · Hassanein M et al (2017) Diabetes Res Clin Pract 126:303–16 · NICE NG28 Type 2 diabetes. Risk categories are a shared-decision guide — patients should follow medical advice where fasting is likely to cause harm. Always individualise.